CSIMarket
 
Nurix Therapeutics Inc   (NRIX)
Other Ticker:  
 
 
Price: $13.0800 $-0.96 -6.838%
Day's High: $14.78 Week Perf: -7.43 %
Day's Low: $ 13.04 30 Day Perf: 42.02 %
Volume (M): 3,891 52 Wk High: $ 16.11
Volume (M$): $ 50,900 52 Wk Avg: $9.06
Open: $13.97 52 Wk Low: $4.22



 Market Capitalization (Millions $) 711
 Shares Outstanding (Millions) 54
 Employees 100
 Revenues (TTM) (Millions $) 77
 Net Income (TTM) (Millions $) -144
 Cash Flow (TTM) (Millions $) -10
 Capital Exp. (TTM) (Millions $) 8

Nurix Therapeutics Inc
Nurix Therapeutics Inc is a biopharmaceutical company that specializes in developing targeted protein modulation drugs for the treatment of various diseases. The company was founded in 2013, and is headquartered in San Francisco, California.

Nurix's technology platform is based on the discovery and understanding of the ubiquitin proteasome system (UPS), a naturally occurring biological process that regulates the degradation and recycling of proteins in cells. The company's approach involves using small molecule drugs to precisely target proteins within the UPS, thereby treating diseases at their root cause.

Nurix's research and development programs are focused on two key areas: oncology and immunology. Within oncology, the company is developing drugs to target specific cancer-causing genes, with the goal of creating more effective and targeted cancer therapies. In immunology, the company is developing drugs to treat inflammatory diseases, such as autoimmune disorders and graft-versus-host disease.

One of Nurix's most promising drug candidates is NX-2127, a small molecule drug designed to degrade the protein BCL-6, which is involved in the development of several types of lymphoma. The company has completed preclinical studies on NX-2127, and is currently advancing the drug into Phase 1 clinical trials.

Nurix has partnerships and collaborations with several major pharmaceutical companies, including Gilead Sciences, Eli Lilly, and Sanofi. These collaborations allow Nurix to leverage its expertise in protein modulation to develop new therapies in areas such as oncology, immunology, and neurology.

Overall, Nurix Therapeutics Inc is a cutting-edge biopharmaceutical company that is revolutionizing the treatment of diseases through its innovative protein modulation technology platform. With a focus on oncology and immunology, the company is well-positioned to make a significant impact on the healthcare industry in the years to come.


   Company Address: 1700 Owens Street San Francisco 94158 CA
   Company Phone Number: 660-5320   Stock Exchange / Ticker: NASDAQ NRIX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Nurix Therapeutics Rejoices as U.S. FDA Lifts Partial Clinical Hold, Enabling Fresh Enrollment for NX-2127 Phase 1 Trial in r/r B-cell Malignancies

Published Mon, Mar 11 2024 11:00 AM UTC

In a major development for the field of oncology, Nurix Therapeutics recently announced the lifting of a partial clinical hold on its Phase 1a/1b study of NX-2127. The U.S. Food and Drug Administration (FDA) has granted Nurix permission to enroll new patients in the trial, thereby resuming their investigation into the potential of this promising therapy in the treatment of r...

Nurix Therapeutics Inc

Breaking: Nurix Therapeutics Inc. Records Astonishing Revenue Growth, but Fails to Unlock Profitability in Latest Fiscal Report

In a major breakthrough, Nurix Therapeutics has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its drug candidate, NX-5948. The company aims to use this drug to treat patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This designation comes after positive Phase 1 data was presented at the American Society of Hematology, supporting Nurix's strategy to develop NX-5948 for CLL and other non-Hodgkin lymphoma indications.
The FDA's Fast Track Designation is a highly significant milestone that expedites the development and review process for promising drugs that address serious medical conditions and unmet needs. This designation provides several advantages, including increased communication with the FDA, eligibility for accelerated approval, and the possibility of priority review. This highlights the potential significance of NX-5948 in the treatment of CLL and SLL.

Clinical Study

Nurix Therapeutics' NX-5948 Receives Fast Track Designation for Relapsed or Refractory CLL and SLL Treatment

Published Tue, Jan 16 2024 9:01 PM UTC

In a groundbreaking development, Nurix Therapeutics has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for its drug candidate NX-5948, aimed at treating patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This designation follows the presentation of positive Phase 1 data at the Amer...

Management Announcement

Nurix Therapeutics Faces Financial Challenges Amid Advances in Targeted Protein Modulation for Cancer and Autoimmune Diseases

Published Mon, Jan 8 2024 12:00 PM UTC



Nurix Therapeutics, a biopharmaceutical company focused on targeted protein modulation for the treatment of cancer and autoimmune diseases, has recently outlined its 2024 strategic priorities. The company plans to advance its pipeline and prioritize the enrollment acceleration of NX-5948 for leukemia and lymphoma based on positive Phase 1 data. However, behind thes...

Clinical Study

Nurix Therapeutics: Blazing Paths in Hematological Therapies and Achieving Robust Financial Growth: A Promising Future on the Horizon

Published Mon, Dec 11 2023 5:00 PM UTC


In the rapidly evolving world of medical therapeutics, Nurix Therapeutics Inc has made significant strides forward with its novel Bruton's Tyrosine Kinase (BTK) degrader programs, NX-5948 and NX-2127. Evidence of this ongoing progress was presented at the 65th American Society of Hematology (ASH) Annual Meeting, putting a sweet spotlight on Nurix's innovative efforts. <...






 

Nurix Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Nurix Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Nurix Therapeutics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com